It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Inhaled hypertonic saline (HTS) treatment is used to improve lung health in patients with cystic fibrosis (CF). The current consensus is that the treatment generates an osmotic gradient that draws water into the airways and increases airway surface liquid (ASL) volume. However, there is evidence that HTS may also stimulate active secretion of ASL by airway epithelia through the activation of sensory neurons. We tested the contribution of the nervous system and airway epithelia on HTS-stimulated ASL height increase in CF and wild-type swine airway. We used synchrotron-based imaging to investigate whether airway neurons and epithelia are involved in HTS treatment-triggered ASL secretion in CFTR−/− and wild-type swine. We showed that blocking parasympathetic and sensory neurons in airway resulted in ~50% reduction of the effect of HTS treatment on ASL volume in vivo. Incubating tracheal preparations with inhibitors of epithelial ion transport across airway decreased secretory responses to HTS treatment. CFTR−/− swine ex-vivo tracheal preparations showed substantially decreased secretory response to HTS treatment after blockage of neuronal activity. Our results indicated that HTS-triggered ASL secretion is partially mediated by the stimulation of airway neurons and the subsequent activation of active epithelia secretion; osmosis accounts for only ~50% of the effect.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 University of Saskatchewan, Department of Physiology, Health Science Building, Room 2D01, 107 Wiggins Rd., Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
2 University of Saskatchewan, Department of Medicine, Division of Respirology, Critical Care, and Sleep Medicine, Royal University Hospital, 103 Hospital Drive, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)
3 Canadian Light Source Inc., 44 Innovation Boulevard, Saskatoon, Canada (GRID:grid.423571.6) (ISNI:0000 0004 0443 7584)
4 University of California, Department of Molecular and Cell Biology, 231 LSA, Berkeley, USA (GRID:grid.47840.3f) (ISNI:0000 0001 2181 7878)
5 University of Saskatchewan, Department of Anatomy and Cell Biology, Health Science Building, Room 2D01, 107 Wiggins Rd., Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)